# CSPC Zhongnuo Pharmaceutical trials: 30

ClinicalTrials.gov lists 30 trials with CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. as lead sponsor, 17 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.: 30 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/cspc-zhongnuo-pharmaceutical-shijiazhuang-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 30
- Recruiting or not yet: 17
- Read on: November 19, 2026

## Trials

The 25 newest of 30, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07943520 | A Study of SYH2053 Injection in Participants With Hepatic Impairment Compared to Participants With Normal Hepatic Function | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 1 | Recruiting | Hepatic Impairment | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943520) |
| November 16, 2026 | NCT07940075 | SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension . | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 2 | Recruiting | Mild to Moderate Primary Hypertension | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940075) |
| November 16, 2026 | NCT07938034 | A Study of SYH2053 Injection in Participants With Renal Impairment Compared to Participants With Normal Renal Function | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 1 | Recruiting | Renal Impairment | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938034) |
| July 10, 2026 | NCT07695597 | A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 2 | Recruiting | Mixed Hyperlipidemia | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07695597) |
| June 10, 2026 | NCT07640217 | A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 2 | Not yet recruiting | Adult Participants With Elevated Lipoprotein(a) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07640217) |
| June 9, 2026 | NCT07635914 | A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 3 | Not yet recruiting | Resistant Hypertension | 382 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07635914) |
| May 15, 2026 | NCT07591298 | Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial... | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 2 | Recruiting | Diagnosed With HoFH | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07591298) |
| April 23, 2026 | NCT07547384 | Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Not applicable | Not yet recruiting | Schizophrenia | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07547384) |
| March 25, 2026 | NCT07493551 | A Bioequivalence Study of PP3M in Patients With Schizophrenia | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Not applicable | Recruiting | Schizophrenia | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493551) |
| March 11, 2026 | NCT07465263 | A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 3 | Recruiting | Heterozygous Familial Hypercholesterolemia (HeFH) | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07465263) |
| February 19, 2026 | NCT07421297 | A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed... | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 3 | Recruiting | Non-familial Hypercholesterolemia and Mixed Hyperlipidemia | 760 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421297) |
| February 19, 2026 | NCT07421284 | A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia... | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 3 | Not yet recruiting | Non-familial Hypercholesterolemia and Mixed Hyperlipidemia | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421284) |
| February 19, 2026 | NCT07421232 | A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 2 | Completed | Hypercholesterolemia and Mixed Hyperlipidemia | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421232) |
| December 5, 2025 | NCT07268430 | Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Not applicable | Completed | Schizophrenia | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07268430) |
| November 21, 2025 | NCT07241923 | A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 1 | Recruiting | Healthy Subjects (HS) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241923) |
| November 21, 2025 | NCT07241910 | A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 1 | Recruiting | Healthy Subjects | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241910) |
| July 31, 2025 | NCT07096869 | Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 1 | Recruiting | Bioequivalence | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07096869) |
| February 24, 2025 | NCT06842537 | Study of SYH2062 Injection in Healthy Chinese Volunteers | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 1 | Recruiting | Healthy Chinese Volunteers | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06842537) |
| August 9, 2024 | NCT06543966 | Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 3 | Unknown | Post-operative Nausea and Vomiting (PONV) | 486 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06543966) |
| January 29, 2024 | NCT06229548 | A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 1 | Completed | Hyperlipemia | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06229548) |
| December 27, 2023 | NCT06182592 | A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid... | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 3 | Unknown | High-risk (Secondary) Acute Myeloid Leukemia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06182592) |
| June 22, 2023 | NCT05913921 | Bioequivalence of Amphotericin B Liposome for Injection | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 1 | Completed | Bioequivalence | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05913921) |
| April 6, 2023 | NCT05801835 | A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Not applicable | Unknown | Acute Myeloid Leukemia | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05801835) |
| March 24, 2023 | NCT05783557 | A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 3 | Unknown | Hypertensive Emergency | 398 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05783557) |
| February 8, 2023 | NCT05717764 | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With... | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 3 | Not yet recruiting | Recurrent Metastatic Nasopharyngeal Carcinoma | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05717764) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 2 | 7 |
| Phase 3 | 8 |
| Not applicable | 5 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 12 |
| Unknown | 6 |
| Completed | 6 |
| Not yet recruiting | 5 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hyperlipoproteinemia Type II | 4 |
| Leukemia, Myeloid, Acute | 3 |
| Schizophrenia | 3 |
| Hypertensive Crisis | 1 |
| Neoplasm Metastasis | 1 |
| Hyperlipidemias | 1 |
| Vomiting | 1 |
| Renal Insufficiency | 1 |
| Nasopharyngeal Carcinoma | 1 |
| Hypercholesterolemia | 1 |
| Neuromyelitis Optica | 1 |
| Recurrence | 1 |
| Multiple Myeloma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Fmcg wholesalers in the United States](https://specstream.ai/data/businesses/fmcg-wholesalers/united-states)
- [Locksmiths in the United States](https://specstream.ai/data/businesses/locksmiths/united-states)
- [Produce wholesalers in the United States](https://specstream.ai/data/businesses/produce-wholesalers/united-states)
- [Truck and industrial vehicle companies in the United States](https://specstream.ai/data/businesses/truck-and-industrial-vehicle-companies/united-states)
- [B2B water treatment companies in the United States](https://specstream.ai/data/businesses/b2b-water-treatment-companies/united-states)
